Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Fase I-studie van een onderzoeksgeneesmiddel tegen pokken

9 september 2026 bijgewerkt door: SIGA Technologies

Een gerandomiseerde, dubbelblinde, cross-over, verkennende fase I-studie van de farmacokinetiek van een enkelvoudige orale dosis van vorm I- versus vorm V-capsules van de anti-orthopoxvirusverbinding ST-246® bij gevoede, normaal gezonde vrijwilligers

The purpose of this study was to evaluate the pharmacokinetic parameters and safety of a single dose of ST-246 400mg Form I versus ST-246 400mg Form V capsules in fed normal healthy volunteers.

Studie Overzicht

Gedetailleerde beschrijving

This was a Phase I, double-blind, cross-over, single-dose study of the orally administered anti-orthopoxvirus compound, ST-246, to 12 healthy, fed volunteers between the ages of 18 and 50 years. Subjects were randomized such that 6 subjects received either ST-246 Form I (monohydrate) followed 10 days later after a wash-out period by Form V (hemihydrate), and 6 subjects received ST-246 Form V followed by Form I, as for the previous group.

Both forms of ST-246 were similar in the way they were manufactured. The only difference between Form I and Form V may be related to how it dissolves, and this may affect the way that it is absorbed in the human body. Information about any side-effects that may occur will also be collected in this study.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

12

Fase

  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Florida
      • Orlando, Florida, Verenigde Staten, 32809
        • Orlando Clinical Research Center

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 50 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. 18 to 50 years
  2. Available for clinical follow-up duration of study.
  3. Able/willing to give written consent.
  4. Good general health; no clinically significant medical history.
  5. Refrain from taking any medications from screening through 72 hours after last dose.
  6. Adequate venous access.
  7. PE and lab results without clinically significant findings within 28 days prior to receipt of drug.
  8. Meet Lab Criteria within 28 days prior to receipt of drug.
  9. Negative pregnancy test
  10. Non smokers
  11. No alcohol or caffeine
  12. Participant or partner has undergone surgical sterilization, or the participant agrees either to be abstinent or use two non-hormonal methods of contraception for duration of the study

Exclusion Criteria:

  1. Marked baseline prolongation of QT/corrected QT interval (QTc) interval (

  2. History of additional risk factors for Torsade de Pointes

  3. Clinically significant abnormal ECG

  4. Personal history of cardiac disease, symptomatic or asymptomatic arrhythmias, syncopal episodes, or prolongation of the PR interval

  5. Family history of Sudden Cardiac Death not clearly due to acute myocardial infarction.

  6. History of any clinically significant conditions including:

    • Asthma
    • Diabetes mellitus
    • History of thyroidectomy or thyroid disease
    • Serious angioedema episodes
    • Head trauma resulting in a diagnosis of TBI other than concussion
    • Seizure or history of seizure
    • Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with intramuscular injections or blood draws
    • Malignancy
  7. Family history of idiopathic seizures

  8. History or presence of neutropenia or other blood dyscrasia

  9. Known Hepatitis B or Hepatitis C infection

  10. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome illness.

  11. Current or recent history of a clinically significant bacterial, fungal, or mycobacterial infection.

  12. Known clinically significant chronic viral infection (or current clinically significant viral infection

  13. History of frequent or severe headaches or migraines

  14. Known chronic bacterial, mycobacterial, fungal, parasitic, or protozoal infection

  15. Woman who is pregnant or is breast-feeding or planning to become pregnant

  16. On any concomitant medications

  17. History of drug allergy that, in the opinion of the PI, contraindicates participation in the trial.

  18. Inability to swallow medication

  19. Body Mass Index above 35 or below 18,

  20. Current drug abuse or alcohol abuse.

  21. Inability to refrain from physical exercise for a period of 24 hr before and after a PK day or refrain from consuming xanthines, grapefruit or grapefruit juice

  22. Clinically significant lactose intolerance

  23. Received experimental drug within 30 days

  24. Vaccination within 30 days

  25. Total of more than 350 milliliters (mL) of blood drawn in 2 months

  26. Treatment with any immunosuppressant or immunomodulatory medication in 3 months

  27. Any condition occupational reason or other responsibility that, in the judgment of the PI, would jeopardize the safety or rights of a subject participating in the trial or would render the subject unable to comply with the protocol

  28. History or diagnosis that would affect absorption of study medication

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Crossover-opdracht
  • Masker: Verdrievoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Actieve vergelijker: Group ST-246 Form I (followed by Form V)

Each of six subjects receive a single oral 400 mg dose (2×200 mg) of ST-246 Form I (monohydrate) in the first intervention period, followed 10 days later (3 days post-treatment monitoring and 7 days wash-out period) in the second intervention period by a single oral 400 mg dose (2×200 mg) of ST-246 Form V (hemihydrate). Both forms of drug are orally administered within 30 minutes after a standard light meal consisting of 400-450 calories and approximately 25% fat.

First Intervention is on Days 1 - 3, and includes 6 patients dosed once orally with ST-246 Form I (Arm 1), and 6 patients dosed once orally with ST-246 Form V (Arm 2).

Andere namen:
  • Tecovirimat

Second Intervention is on Days 11 - 13 (after a 3 day post-treatment monitoring and 7 day wash-out period) where the 6 patients previously given ST-246 Form I (Arm 1) are now dosed once orally with ST-246 Form V, and the 6 patients previously given ST-246 Form V (Arm 2) are now dosed once orally with ST-246 Form I.

Andere namen:
  • Tecovirimat
Actieve vergelijker: Group ST-246 Form V (followed by Form I)

Each of six subjects receive a single oral 400 mg dose (2×200 mg) of ST-246 Form V (hemihydrate) in the first intervention period, followed 10 days later (3 days post-treatment monitoring and 7 days wash-out period) in the second intervention period by a single oral 400 mg dose (2×200 mg) of ST-246 Form I (monohydrate). Both forms of drug are orally administered within 30 minutes after a standard light meal consisting of 400-450 calories and approximately 25% fat.

First Intervention is on Days 1 - 3, and includes 6 patients dosed once orally with ST-246 Form I (Arm 1), and 6 patients dosed once orally with ST-246 Form V (Arm 2).

Andere namen:
  • Tecovirimat

Second Intervention is on Days 11 - 13 (after a 3 day post-treatment monitoring and 7 day wash-out period) where the 6 patients previously given ST-246 Form I (Arm 1) are now dosed once orally with ST-246 Form V, and the 6 patients previously given ST-246 Form V (Arm 2) are now dosed once orally with ST-246 Form I.

Andere namen:
  • Tecovirimat

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: t½
Tijdsspanne: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs

Mean terminal half-life (t½; hrs) for Forms I and V were calculated from [plasma] vs time profiles.

Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: AUC0-τ
Tijdsspanne: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs

Area under the drug concentration-time curve from time zero to time t, where t is the last timepoint with a drug concentration ≥ lowest obtainable quantification (AUC0-τ; ng*hr/mL).

Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: AUC0-∞
Tijdsspanne: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs

Area under the drug concentration-time curve from time zero to infinity (AUC0-∞; ng*hr/mL).

Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: Cmax
Tijdsspanne: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs

Maximum drug concentration in plasma, determined directly from individual concentration-time data (Cmax)

Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: Tmax
Tijdsspanne: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs

Time to maximum plasma concentration(Tmax; hrs) for Forms I and V were calculated from [plasma] vs time profiles.

Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Number of Study Participants Who Tolerated a Single Dose of ST-246 Form I vs. Form V as Determined by No Clinically Significant Changes in Safety Parameters
Tijdsspanne: 4 weeks

Evaluated safety parameters included:

  1. physical examination/vital signs
  2. electrocardiograms (heart rate, PR interval, QRS duration, QT interval, and QTc Bazett)
  3. laboratory safety tests (hematology, chemistry, urinalysis)
  4. adverse events For a), b) and c), summary statistics (mean,SD, median, minm, maxm)for values, and changes from baseline(Day 1 pre-dose) to each timepoint, were measured and compared to laboratory normal reference ranges. Values for a)- d) were assigned grades according to DAIDS AE Grading Table. Any Grade of 3 or higher was considered severe and significant.
4 weeks

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Thomas C Marbury, MD, Orlando Clinical Research Center

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start

1 augustus 2008

Primaire voltooiing (Werkelijk)

1 oktober 2008

Studie voltooiing (Werkelijk)

1 oktober 2008

Studieregistratiedata

Eerst ingediend

1 augustus 2008

Eerst ingediend dat voldeed aan de QC-criteria

5 augustus 2008

Eerst geplaatst (Geschat)

6 augustus 2008

Updates van studierecords

Laatste update geplaatst (Werkelijk)

1 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

9 september 2026

Laatst geverifieerd

1 september 2010

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • SIGA-246-005
  • HHSN266200600014C (Ander subsidie-/financieringsnummer: NIAID)

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren